ABB India Limited (BOM:500002)

Verve Therapeutics Income Statement

Financials in millions INR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	126,003	121,883	104,465	85,675	69,340	58,210
Other Revenue	117.8	-	-	-	-	-
Revenue	126,121	121,883	104,465	85,675	69,340	58,210
Revenue Growth (YoY)	10.27%	16.67%	21.93%	23.56%	19.12%	-20.42%
Cost of Revenue	74,735	71,288	66,455	55,900	46,619	38,991
Gross Profit	51,386	50,595	38,010	29,775	22,721	19,219
Selling, General & Admin	8,717	8,346	7,222	6,457	6,096	5,708
Other Operating Expenses	20,383	19,415	15,450	13,175	11,041	10,665
Operating Expenses	30,458	29,050	23,871	20,680	18,164	17,576
Operating Income	20,928	21,545	14,139	9,096	4,558	1,643
Interest Expense	-159.8	-154	-122.7	-112.8	-91	-101.8
Interest & Investment Income	3,433	3,433	2,770	1,268	686.2	677.2
Currency Exchange Gain (Loss)	-286.3	278.7	-371	-488.3	405.7	47.6
Other Non Operating Income (Expenses)	272.5	90.6	242.7	508.7	488.3	312.1
EBT Excluding Unusual Items	24,187	25,193	16,659	10,271	6,047	2,578
Merger & Restructuring Charges	-	-	-	-	-	-135
Gain (Loss) on Sale of Assets	-60.5	-60.5	-69.7	-35.5	-17.7	12.5
Other Unusual Items	-	-	-	3,393	1,213	587.9
Pretax Income	24,127	25,133	16,589	13,628	7,243	3,044
Income Tax Expense	6,141	6,387	4,107	3,372	1,918	739.3
Earnings From Continuing Operations	17,986	18,746	12,482	10,256	5,325	2,304
Earnings From Discontinued Operations	-33.5	-29.7	-61.3	-93.8	-127.8	-112.2
Net Income	17,952	18,716	12,421	10,162	5,197	2,192
Net Income to Common	17,952	18,716	12,421	10,162	5,197	2,192
Net Income Growth	11.90%	50.69%	22.22%	95.54%	137.07%	-27.75%
Shares Outstanding (Basic)	212	212	212	212	212	212
Shares Outstanding (Diluted)	212	212	212	212	212	212
Shares Change (YoY)	0.01%	-	-	-	-	-
EPS (Basic)	84.71	88.32	58.61	47.96	24.53	10.35
EPS (Diluted)	84.71	88.32	58.61	47.96	24.53	10.34
EPS Growth	11.89%	50.69%	22.22%	95.54%	137.18%	-27.77%
Free Cash Flow	8,787	11,179	11,684	5,740	4,779	1,968
Free Cash Flow Per Share	41.46	52.75	55.14	27.09	22.55	9.29
Dividend Per Share	43.270	44.160	23.800	5.500	5.200	5.000
Dividend Growth	25.57%	85.55%	332.73%	5.77%	4.00%	4.17%
Gross Margin	40.74%	41.51%	36.38%	34.75%	32.77%	33.02%
Operating Margin	16.59%	17.68%	13.54%	10.62%	6.57%	2.82%
Profit Margin	14.23%	15.36%	11.89%	11.86%	7.50%	3.77%
Free Cash Flow Margin	6.97%	9.17%	11.19%	6.70%	6.89%	3.38%
EBITDA	22,001	22,549	15,077	9,945	5,363	2,592
EBITDA Margin	17.44%	18.50%	14.43%	11.61%	7.73%	4.45%
D&A For EBITDA	1,073	1,004	937.5	849.2	804.7	948.3
EBIT	20,928	21,545	14,139	9,096	4,558	1,643
EBIT Margin	16.59%	17.68%	13.54%	10.62%	6.57%	2.82%
Effective Tax Rate	25.45%	25.41%	24.76%	24.74%	26.48%	24.29%
Revenue as Reported	129,837	125,417	107,482	87,470	70,936	59,326

Updated Feb 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.